Human Domain Antibodies against Virulence Traits of Candida albicans Inhibit Fungus Adherence to Vaginal Epithelium and Protect against Experimental Vaginal Candidiasis
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Antibody variable domains (domain antibodies [DAbs]) are genetically engineered antibody fragments that include individual heavy-chain (VH) or kappa-chain (Vkappa) variable domains and lack the Fc region. Human DAbs against the 65-kDa mannoprotein (MP65) or the secretory aspartyl proteinase (SAP)-2 of Candida albicans (monospecific DAbs) or against both fungal antigens (heterodimeric, bispecific DAbs) were generated from phage expression libraries. Both monospecific and bispecific DAbs inhibited fungus adherence to the epithelial cells of rat vagina and accelerated the clearance of vaginal infection with the fungus. When heterodimeric DAbs were used, the clearance of infection was at least equivalent to treatment with fluconazole. The in vivo protective effects of DAbs were demonstrated by both pre- and postchallenge schedules of DAb administration and with both fluconazole-susceptible and fluconazole-resistant strains of C. albicans. This is the first demonstration that human DAbs lacking the Fc constituent can efficiently control an infection and can act largely by inhibiting adherence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Virulence factors of Candida albicans
Calderone, R. A., & Fonzi, W. A. (2001) · Trends in Microbiology · doi:10.1016/s0966-842x(01)02094-7 · Cited by 1,331
Candida albicans Secreted Aspartyl Proteinases in Virulence and Pathogenesis
Naglik, J. R., Challacombe, S. J., & Hube, B. (2003) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.67.3.400-428.2003 · Cited by 1,179 · cited 1×
“zymatic activity, which is relevant for adherence [23, 34].”
BackgroundRibeiro, M. A., Paula, C. R., Perfect, J. R., & Cox, G. M. (2005) · Medical Mycology · doi:10.1080/13693780500093838 · Cited by 27 · cited 1×
“duced in vitro susceptibility to the azoles [35].”
Background
Cited by
Sobel, J. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60917-9 · Cited by 1,270
The making of bispecific antibodies
Brinkmann, U., & Kontermann, R. E. (2017) · mAbs · doi:10.1080/19420862.2016.1268307 · Cited by 923
Candida Infections of the Genitourinary Tract
Achkar, J. M., & Fries, B. C. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00076-09 · Cited by 736
“albicans have recently been shown to inhibit fungal adherence to vaginal epithelium and protect against experimental vaginitis in rats (66).”
BackgroundAntibody Structure and Function: The Basis for Engineering Therapeutics
Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 638
Alternative molecular formats and therapeutic applications for bispecific antibodies
Spiess, C., Zhai, Q., & Carter, P. J. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.01.003 · Cited by 607
“Subsequently human dAbs were used in the construction of BsAb fragments (De Bernardis et al., 2007).”
MethodKushnir, N., Streatfield, S. J., & Yusibov, V. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.10.083 · Cited by 587
Candida albicans Cell Wall Proteins
Chaffin, W. L. (2008) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00032-07 · Cited by 515
Dual targeting strategies with bispecific antibodies
Kontermann, R. (2012) · mAbs · doi:10.4161/mabs.4.2.19000 · Cited by 435
Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange
Labrijn, A. F., Meesters, J. I., de Goeij, B. E. C. G., van den Bremer, E. T. J., Neijssen, J., van Kampen, M. D., Strumane, K., Verploegen, S., Kundu, A., Gramer, M. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220145110 · Cited by 339
Candida albicans interactions with epithelial cells and mucosal immunity
Naglik, J. R., Moyes, D. L., Wächtler, B., & Hube, B. (2011) · Microbes and Infection · doi:10.1016/j.micinf.2011.06.009 · Cited by 277
Patients with Long-Term Oral Carriage Harbor High-Persister Mutants of Candida albicans
LaFleur, M. D., Qi, Q., & Lewis, K. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00860-09 · Cited by 237
Interactions of Candida albicans with epithelial cells
Zhu, W., & Filler, S. G. (2010) · Cellular Microbiology · doi:10.1111/j.1462-5822.2009.01412.x · Cited by 223
“Importantly, single-chain, domain-specific antibodies directed against Mp65 are able to block the adherence of wild-type C. albicans yeast cells to vaginal epithelial cells in an ex vivo assay (De Bernardis et al., 2007).”
BackgroundEvolution in Candida albicans Populations During a Single Passage Through a Mouse Host
Forche, A., Magee, P. T., Selmecki, A., Berman, J., & May, G. (2009) · Genetics · doi:10.1534/genetics.109.103325 · Cited by 147
“ Candida Albicans Interactions With The Host: Crossing The Intestinal Epithelial Barrier”
Basmaciyan, L., Bon, F., Paradis, T., Lapaquette, P., & Dalle, F. (2019) · Tissue Barriers · doi:10.1080/21688370.2019.1612661 · Cited by 89
Immune Complex Pathophysiology
NYDEGGER, U. E. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1398.009 · Cited by 31
Naglik, J. R. (2014) · New Journal of Science · doi:10.1155/2014/390241 · Cited by 29
Metadata
- Authors
- De Bernardis, F., Liu, H., O’Mahony, R., La Valle, R., Bartollino, S., Sandini, S., Grant, S., Brewis, N., Tomlinson, I., Basset, R. C., Holton, J., Roitt, I. M., & Cassone, A.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-01
- Volume
- 195
- Issue
- 1
- Pages
- 149-157
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2136371344
- Cited by
- 114
- References
- 3
- FWCI
- 5.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.